Compare NeoGenomics Inc. Common Stock (NEO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NeoGenomics Inc. Common Stock vs 10X Genomics Inc — how do they compare? NeoGenomics Inc. Common Stock trades at $17.2 (market cap $2.17B), while 10X Genomics Inc trades at $70.35 (market cap $9.53B). The key difference: 10X Genomics Inc is far larger — about 4.4× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.
| NEO | TXG | |
|---|---|---|
Market Cap | $2.17B | $9.53B |
Volume | 1,615,943 | 4,138,224 |
Sector | Health | Health |
52-Week High | $19.91 | $97.74 |
52-Week Low | $7.19 | $11.83 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $2.47B | $9.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TXG trades at $71.79, down 4.52% on the day, amid a bearish technical signal. The company shows improving fundamentals with revenue of $642.82M in 2025 and a narrowing net loss of -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory, though insider selling and high valuation ratios like a P/S of 15.13 and EV/EBITDA of 241.6 present concerns.
The outlook is mixed; analyst consensus is a Buy with a $83.30 price target, but execution risks on Atera delivery and sustained profitability remain key. Upside depends on commercial success of new platforms, while downside risks include competitive pressures and failure to achieve positive earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NeoGenomics Inc. Common Stock
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
